Under our immuno-oncology collaboration with TESARO, we have granted exclusive rights to TESARO to develop and commercialize the following AnaptysBio-generated antibody product candidates:
Anti-PD-1 Monospecific Antagonist Antibody (TSR-042): Registration program initiated in Q2 2017;
Anti-TIM-3 Monospecific Antagonist Antibody (TSR-022): Phase 1 clinical trial dosing initiated in the third quarter of 2016 subsequent to the acceptance of a U.S. FDA IND, expect initiation of an anti-PD-1 combination trial in mid-2017;
Anti-LAG-3 Monospecific Antagonist Antibody (TSR-033): U.S. FDA IND filed, expect initiation of Phase 1 study in mid-2017, and
Anti-PD-1/LAG-3 Bispecific Antagonist Antibody: lead candidate identified.
To access scientific publications on this topic, please click here.